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Résumé 
Les suppresseurs de signalisation des cytokines (SOCS) sont une famille des protéines 
qui contrôlent la signalisation des cytokines par l'inhibition des JAK/STATs. Ils fonctionnent 
comme un adapteur pour la formation d'une ligase E3. De cette façon, des protéines SOCS aident 
à la dégradation des JAK et d'autres cibles, incluant d'autres SOCS. SOCS 1 est la protéine la plus 
étudiée de la famille. Elle a été identifiée comme étant nécessaire pour la fonctiori normale du 
développement des lymphocytes. Aussi SOCS 1 est hyperméthylé dans beaucoup des cancers et 
fonctionne comme un suppresseur de tumeurs. Les mécanismes précis de SOCS 1 comme 
suppresseur de tumeurs ne sont pas connus. La plupart des études se concentrent sur Je rôle de 
SOCS 1 dans la dégradation des kinases JAK et l'inhibition de la voie de signalisation de 
JAKISTAT. 
Dans cette étude, nous avons démontré que la surexpression de SOCS 1 induit un arrêt 
permanent dans le cycle cellulaire par l'induction des mécanismes de sénescence. SOCS] 
prévient la formation de colonies dans la lignée de cancéreuse des U20S et rend active la voie de 
signalisation de p53, peut-être par des interactions directes. Nous avons découvert un résidu 
nécessaire, le N 198, qui reste dans le « Cul box» de SOCS 1. Quand ce résidu a subi une mutation 
ou une perturbation, ceci inhibe la capacité de SOCS] à induire l'arrêt de croissance. Le résidu 
N 198 est impliqué dans la capacité de recrutement des cullins, ceci suggère que des séquences 
différentes dans le« Cul box» de SOCSI peuvent lui donner la capacité de se lier avec d'autres 
protéines ce qui lui donne la capacité d'induire un arrêt de croissance et de rendre active la voie 
de p53. D'autres membres de la famille des SOCS ne sont pas capables d'induire un arrêt de 
croissance, alors que SOCS5 semble fonctionner comme oncogène. 
Mots Clés: SOCS: suppresseur de signalisation par les cytokines, JAK : kinase Janus, STA T : 
capteur de signal et activateur de transcription 
IV 
Abstract 
The suppressors of cytokine signaling are a powerful family of proteins shown to 
negatively regulate cytokine signaling by inhibiting the JAKIST AT pathway. By acting as 
adaptor proteins and recruiting the modules of an active E3 ligase, SOCS proteins can degrade 
JAKs and a variety of other target substrates including other SOCS molecu les. SOCS 1 has been 
the most studied ofthe family and has been shown to be vital to normal lymphocyte development. 
As weil it has shown to be silenced via hypermethylation in a variety of cancers and been shown 
to contain the properties ofa tumor suppressor. The exact mechanisms ofSOCSI as a tumor 
suppressor are not known though most theories focus on the degradation of JAK's and inhibition 
of JAK/ST A T signaling. 
Here we demonstrate SOCS 1 overexpression is able to induce permanent cell cycle arrest 
in primary cells by induction of the senescence machinery. It also prevents colony formation in 
the U20S sarcoma line and leads to activation of the p53 pathway, possibly through direct 
interactions. Also we have identified an essential residue, N 198, which when mutated or deleted 
leads to loss of ability to promote growth arrest. This residue is unique to SOCS 1 and lies within 
the Cul box domain of SOCS 1 and is involved in Cullin recruitment. This suggests that 
differential sequences in the Cul box of SOCS 1 compared to other SOCS family proteins may 
allow it to bind to different cullins or other proteins that give it the ability to promote growth 
arrest in a variety of cells and activate the p53 pathway. They also hint towards the fact that 
SOCS 1 induced senescence and growth arrest is independent of its actions on the JAKIST A T 
pathway. Other members of the SOCS family investigated were not able to induce premature 
senescence, while sorne such as SOCS5 promoted cell proliferation. 
Key words: SOCS: suppressor of cytokine signaling, JAK: Janus kinase, ST A T: Signal 
transducer and activator of transcription 
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Cytokine Signaling & Janus kinases 
Cytokines are powerful signaling ligands used to communicate a signal from one 
cell to another and are capable of commencing multiple signaling cascades within a cell 
(1]. Cytokine signaling has been shown to play a large role in growth and differentiation 
though it is largely known for its role in immune responses such as wound healing and 
inflammation. They have also been demonstrated to play roles in development of the 
nervous system, and development during embryogenesis. Cytokines act in a similar 
manner to hormones as they are secreted and pass signais from one cell to the next, 
binding to a membrane bound receptor to commence their cascade within that cell. Most 
cytokines are sm aIl water-soluble proteins or glycoproteins and can be secreted by many 
different cell types. Four groups of cytokines have been classitied based on structure. 
The tirst group is classified as having a four a-helix bundle and can be further divided 
into subfamilies. The three subfamilies are; the interferons (IFN), activated in viral 
response, the interleukin-2 (IL-2) subfamily, which mediates signais to activate 
lymphocytes, and the interleukin-l 0 (IL-l 0) subfamily, which acts as an inhibitory 
molecule and prevents activation of other cytokine pathways such as the IFN and IL-2 
pathways (2-7]. The a-helix bundle group makes up the largest and most weil known 
group of cytokines. The other three groups include the interleukin-l group (among the 
tirst cytokines discovered), interleukin-7 group and a group of cytokines simply classified 
as chemokines (8-11]. 
Each specifie cytokine has its own receptor that in tum is associated with a 
tyrosine kinase from the Janus kinase family (JAKs) [12-15]. The JAK family of kinases 
consists of JAKl, JAK2, JAK3, and a fourth member, TYK2 [12, 13].lt is the JAKs that 
are responsible for downstream activation of aIl other kinases seen involved in cytokine 
signaling. AlI JAKs are similar in size, 120-130Kda. They are characterized by having a 
carboxy terminal kinase domain and pseudo kinase domains that precedes it. JAKs are 
almost ubiquitously expressed except for JAK3, which is found primarily in 
haematopoietic ceIls. 
JAK binding to cytokine receptors can take a variety offorms, which are 
generaIly c1assified into three patterns. JAK2 can bind constitutively, or in response to 
ligands, to single-chain receptors which then aggregate and cause a subsequent 
aggregation of JAK2 [16, 17]. This leads to transphosphorylation of the kinase activation 
loops, activating the JAKs and increasing their catalytic activity. The now activated 
JAK2 is able to phosphorylate the receptor and target substrates recruited by the receptor, 
as well as autophosphorylate itself. A second model involves a pc_chain associated with a 
ligand binding a-chain, JAK2 associated with the pc_chain, which leads to its activation 
and signal transduction [17-19]. This is commonly seen in the lL-3 and 1L-6 families. 
The interferons and 1L-2 family require two chains to induce JAK signaling [20-24]. IFN-
a & p have a p-chain, which associates with JAK2 and a a-chain that associates TYK2 
[21-24]. IFN-y has an a-chain that associates with JAKI and a p-chain that associates 
with JAK2 [23]. This is similar to the 1L-2 receptor, where JAK2 binds to either a ligand 
specific a-chain or the proximal region of the p-chain and JAK3 binds to a shared Yc 
chain, the receptor aggregates bring the two JAKs together [20]. 
Though the mechanisms may vary slightly, the end goal of cytokine binding to a 
receptor is to cause aggregation of the JAKs which leads to their subsequent cross 
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activation and commences the signaling cascade [l, 12, 13, 18, 20]. JAKs can activate 
many signaling cascades by means of recruitment using SH2 domains oftarget 
molecules. Such target molecules include RAS, phosphatidylinositol-3-0H-kinase 
(PI3K), as weIl as the signal transducers of activation and transcription (STA TS). 
STATS 
The ST A TS make up a well-known family of transcription factors heavily linked 
to cytokine/JAK signaling. ST A TS act upon target genes through different mechanisms 
as weB. The first mechanism was found in studies involving INF-a/~, these showed 
ST A Tl was phosphorylated in response to IFN and bound in a complex with p48 [25]. 
This caused ST A TIto enter the nucleus and cause transcription of genes containing IFN 
response elements (lSRE). Later it was shown IFN-y caused phosphorylation of ST A Tl 
which caused it to form a dimer which th an moves into the nucleus and binds to gamma 
activated sequences (GAS) in target genes and drives transcription [26]. As more ST A T 
molecules were cloned, this model became the widely accepted model for ST AT 
activation, and it has since been shown that that almost aIl cytokines activate at least one 
STAT [13]. 
AlI ST AT members contain conserved SH2 domains as weIl as an SH3-like 
domain and a DNA binding domain [13, 27]. Phosphorylation of tyrosine residues in the 
carboxy terminus mediates both hetero and homo di mer formation via the SH2 domains 
[28]. Dimer formation leads to entry into the nucleus where transcription follows [26, 28] 
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ST A TS can also be activated by other serine/threonine kinases and have been linked to 
MAPK and the RAS signaling cascade [26,28-32]. 
Discovery of a SOCS Family of pro teins 
Obviously, cytokines are involved in a variety of important signaling cascades 
and therefore must be carefully regulated. Constitutive activation of any growth or 
proliferation signal, as w~ll as a chronic inflammation response, can have dire 
consequences for the cell, the worst being malignant transformation. As such, another 
family ofproteins known as the suppressors of cytokine signaling (SOCS) exist to 
negatively regulate the em~cts of cytokines through a variety ofmechanisms including 
direct inhibition oftheir receptors or the JAKs which activate them [33-37]. The first 
protein ofthis family was discovered in 1995 and named cytokine induced suppressor 
(CIS) [35]. 
Currently, there are eight known members of the SOCS family in humans 
(SOCSI-7 and CIS) [38]. By studying the primary amino acid sequences of the SOCS 
family members it has been revealed that there exists a high degree of similarity between 
pairs of proteins. For example, SOCS 1 is very similar to SOCS3 and thus they form a 
pair, SOCS2 and CIS make another, while SOCS6&7 and SOCS4&5 round out the 
pairings. SOCS family members a11 share a SH2 domain as well as conserved C-terminal 
SOCS box motif, but have variable N-terminals. The SOCS box domain has since been 
found in a variety of non-SOCS family proteins, over twenty so far [39]. The mechanisms 
4 
of inhibition by SOCS proteins varies from protein to protein, sorne ev en display multiple 
mechanisms. 
SOCS 1 has become the most studied of the group. It was cloned and described by 
three different groups under different studies, which speaks of its versatility as a negative 
regulator of cytokine signaling. Naka et al. were trying to find other STA T family 
members using an antibody for a sequence in the ST A T3 SH2 when they identified both 
CIS and a new gene, which they cloned and named Stat-induced ST A T inhibitor-1 or 
SSI-1 [37]. SSI-1 showed a 36% homology to the SH2 domain ofCIS, but none to 
ST A T3 or ST A T6, except for the phospho-tyrosine recognition site. A second group, 
looking for proteins that could bind to the JAKs directly through the JH1 domain, also 
managed to clone SOCS1, which they at the time had named JAB for Janus kinase 
binding protein·[34]. They too reported a protein with a SH2 domain sharing simi1arity to 
that of CIS (35%). A third group named the protein SOCS 1 after finding it by screening 
for genes encoding proteins that could inhibit IL-6 signa1ing [33]. They performed a 
screen of library of genes from the factor dependent cellline FDC-P 1. Upon infecting Ml 
cells with a retrovirus containing the cDNAs from the FDC-P 1 cells they found a 1.4 Kbp 
insert that rendered the Ml cells unresponsive to the IL-6 signal. They cloned the insert 
and also found it to be a relative of CIS and named it the suppressor of cytokine signaling 
1 (SOCS1). 
The early studies on SOCS 1 alllead to similar results that helped e1ucidate its role 
in cytokine signaling and shed sorne light on the mechanisms through which it works. 
The SOCS1 gene rests on a single exon and is located in mice on chromosome 16, close 
to the protamine gene cluster [33, 34]. It shares no homology to any of the protamine 
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genes, but rather corresponded to what was a then unknown ORF at the 3' ofthese genes 
[34]. It encodes a 212 amino acid prote in in mi ce and rats, 211 in humahs [33,34,37]. 
The human, mouse and rat copies of the protein are highly homologous sharing a 95-99% 
amino acid sequence [33]. SOCSI contains a SH2 domain at amino acids 79-167 and a 
SOCS Box domain at its C-terminus [33,34]. Using the sequence from SOCSI and 
expressed sequence tags (ESTs) Starr et al., were able to clone the first two other related 
SOCS proteins SOCS2 and SOCS3, which have similar SH2, and SOCS box domains as 
SOCS] [33]. SOCS1 expression is ubiquitous in most tissue types though it has been 
repeatedly shown to have higher levels of expression in the thymus, spleen, testes and 
lung [33, 37]. 
Role of SOCS! 
Investigations into the role of SOCS l in cytokine signaling clearly show its role 
as a negative regulator. When expressed in myeloid leukemia (M 1) cells that also 
expressed a Thrombopoietin receptor, SOCS 1 conferred a general resistance to cytokine 
signaling [33]. Furthermore these cells continued to grow and proliferate when 
expressing SOCS 1, even when treated with a variety of cytokines including IL-6, IFN, 
Leukemia inhibitory factor (LIF) and Thrombopoietin (in Ml.mpl cells). Such treatment 
caused parental Ml cells to stop proliferation and form differentiated colonies [33, 37]. 
Treatment with dexamethasone did lead to differentiation in cells expressing SOCS 1, 
implying it acted only in the cytokine signaling pathways, and not the general 
differentiation process [33]. Expressed in NIH3T3 cells, SOCSI was able to block many 
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of the antiviral activities ofIFN [34]. Since SOCS 1 seemed to inhibit cytokine signaling, 
it was suspected that it acted as a negative feedback rnechanism so the effects of cytokine 
signaling on SOCS 1 induction were studied. In growth factor dependent celllines such as 
Ml and the hybridoma MH60 cellline, SOCSl was induced in response to treatment with 
IL-6 and soluble IL-6 receptor [37]. This was repeated in the IL-4 dependent line CT4S 
after treatment with IL-4 as weIl as the G-CSF dependent NFS60 line with G-CSF 
treatment. Bone marrow ce Ils stirnulated with different cytokines are capable of not only 
inducing SOCS1, but also a variety of SOCS family members, depending on the cytokine 
[33]. Also sorne cytokines are capable of inducing certain SOCS genes in specific cell 
lines but not others. IL-3 and activation of the erythropoietin receptor (EPO) are unable 
to induce SOCS1 in Tf-l and NFS60 cells. IL-6 induces CIS, SOCSl-3, in mi ce liver cells 
but only C1S and SOCS1 in Ml ceIls, displaying a cell specific cytokine response in the 
induction of SOCS family members. 
Since SOCSI inhibits many cytokines, and most cytokine signaIing cascades 
signal through the JAKISTAT pathway, the interactions between SOCS 1 and the 
JAKISTA T pathway were further studied. IL-6 and IL-4 are inhibited by SOCS l and are 
both capable of inducing SOCSl. Both act through the JAKIST A T pathway, IL-6 through 
ST A T3 and IL-4 through ST A T6. Studies of the SOCS l promoter revealed binding 
sequences for ST A T3 and ST A T6, implicating SOCS1 as a target gene for ST AT 
signaling. It has since been shown that SOCS1 also has binding sites for ST A T5 as weIl 
in its promoter. Ml cells transfected with SOCSl and STAT3 show induction ofSOCSI 
rnRNA in response to IL-6. However when SOCS 1 is co-expressed with a ST A T3 
mutant, in which a tyrosine reside phosphorylated by a JAK (Y705) is replaced with a 
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phenylalanine, no induction takes place, showing a requirement for activated ST AT 
signaling as a requirement for the induction of SOCS] [37]. 
Tyrosine phosphorylation ofSTAT3 and the Gp130 protein, which is part of the 
cytokine receptor and is phosphorylated by JAKs, were both reduced in Ml cells 
expressing SOCS]. IL-6 treatment is able to phosphorylate both STAT3 and Gp130 in 
normal Ml cells, though expression of SOCS] reduces this .. STAT3 and STAT5 tyrosine 
phosphorylation was also reduced in 293 cells expressing SOCS]. General ST AT 
activation in response to many cytokines is greatly inhibited by SOCS 1; ST A T5 
activation by EPO and ST A T3 activation by IL-6 is almost completely aboli shed in 
SOCS] expressing Ml cells [34]. As well several STAT target genes su ch as the 
immunoglobin fragment Fcy recptor (FcyR) show a large reduction in expression in 
SOCS] Ml cells. 
SOCS 1 also pre vents ST AT molecules from forming dimers that enter the 
nucleus, preventing their activation ofDNA transcription [33]. In Ml cells treated with 
IL-6, the most common dimers observed are the SIF-A (STAT3 homodimer) and SIF-B 
(STATl/STAT3 heterodimer), the formation ofthese complexes is observed using 
electrophoretic mobility shift assays. In SOCS] expressing cells IL-6 treatment fails to 
induce formation ofthese dimers, as well it also blocks formation of the SIF-C STATI 
homodimer induced by IFN-y. Hence SOCSI is able to prevent tyrosine phosphorylation 
of ST A Ts, preventing them from forming an active heterodimer and blocking 
transcription of ST AT target genes in the process. 
SOCS 1 does not directly bind and inhibit the ST AT transcription factors. Instead 
it targets the JAKs that activate them and inhibits their signaling cascade. SOCS 1 directly 
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interacts with the JH 1 domain of JAK2 via its SH2 domain and has been shown to 
interact with TYK2 as well [34,37]. However, JAK activity is needed for this interaction 
as SOCS 1 does not interact with a K882D kinase defective mutant copy of JAK2. When 
co-expressed in 293 cells JAK2 tyrosine phosphorylation levels are much lower than in 
control 293 cells not overexpressing SOCS]. However, phosphorylation at a key residue 
YI 007, is necessary to activate the JAK2 and needs to occur before SOCS 1 can bind. 
This implies that upon activation of the JAK2, SOCS 1 is able to binds to JAK2 and 
inhibit its autophosphorylation and subsequent phosphorylation of cytokine receptors, 
ST AT molecules and their target genes. Therefore, it is through inhibition of the activity 
of the JAKs that SOCS 1 confers a resistance to cytokines and negatively regulates their 
signaling cascades. 
When JAK2 and ST A T3 are co-expressed in 293 cells, ST AT3 undergoes a rise in 
tyrosine phosphorylation. The same occurs when STAT5 is co-expressed with JAK2. If 
JAK2, SOCS 1 and STAT3/STAT5 are aIl expressed together, no phosphorylation of 
ST A T3 or ST AT5 occurs. Furthennore, SOCS 1 is capable of preventing phosphoryIation 
of JAK 1 and JAK3 in 293 cells as weil, indicating SOCS 1 is capable of regulating a 
broad spectrum of JAKISTAT signaling pathways other thanjust JAK2. SOCSl is able to 
inhibit IL-2 and IL-3 activation of the c-fos promoter as well [34]. Since STATS are not 
required to activate c-fos but JAKS are, it demonstrates that SOCS 1 directly targets the 
JAKs not the ST A Ts themselves [34, 40]. 
The inhibitory mechanisms of SOCS 1 seem to be restricted specifically to the 
JAKISTAT pathway. Whereas SOCSl inhibits 1L-2 and lL-3 activation ofc-fos, it does 
nothing to prevent c-fos activation by cAMP (which follows a non cytokine activation 
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and does not involve the JAKs) [34]. When expressed in NII-l3T3 cells SOCSl does not 
alter tyrosine-phosphorylation of Erk2 and Shc in response to fibroblast growth factor 
(FGF). SOCS 1 binds the kinase domain of c-kit in yeast cells but fails to inhibit c-kit or 
the epidermal growth factor receptor. This demonstrates that SOCSl targets specifically 
the JAK tyrosine kinase activity and not tyrosine kinases in general. 
SOCS] and the immune system 
SOCS1 plays a central role in the deve10pment of the immune system. SOCS1 
knockout mice show many phenotypes, among them T -cell associated lyrnphoma and 
large scale infiltration of macrophages, lymphocyte and eosinophils [41-43]. These mice 
die very young due to overactive IFNy signaling, the majority coming from T-cells [43]. 
They have been shown to suffer symptoms such as liver necrosis, myocarditis, 
polymyositis and fatty degeneration. SOCS1 has been shown to induce resistance to IFNy 
when overexpressed [44]. In SOCS 1 knockout mice lacking T -cells or containing a knock 
out ofIFNy, the same rates of young lymphocyte-dependent lethality are not seen as they 
are in normal SOCS 1 -1- mice [43,45]. Macrophages isolated from SOCS 1 -1- rnice 
require little IFNy to bec orne activated, as compared to normal wild type mice [46]. As 
weB these rnice show higher levels ofnatural killer T-cells (NKT), which are implicated 
in the necrosis of the liver [42]. 
Regulation of T cell developrnent has been shown to be controlled directly by 
SOCS 1. SOCS 1 has been shown to be expressed in the thymus, especially during 
thyrnocyte development [33, 34, 37, 47, 48]. Expression ofSOCS1 is critical for the 
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proper development of CD4+ T cells [49]. Deficiencies of SOCS 1 lead to increases in 
CD8+ CD4- ceUs and CD4+CD8+ double positive cells, but leads to decreases in 
CD4+CD8- cells [47,49]. This is caused through increased levels in IL-7 signaling, which 
protects double positive cells, and IL-5 which stimulates the proliferation of CD8+ CD4-
celIs, both cytokines are usually negatively regulated by SOCSl [47,50,51]_ The 
number of total T lymphocytes in SOCSl deficient mice is also increased [52]. 
SOCS3 has also been shown to play a large role in regulation of macrophages and helper 
T~cells, placing the SOCS family ofproteins in the middle ofT-celI development and 
regulation of normal immune system development [53, 54]. 
Other immune cells such as dendritic cells are also under SOCS 1 control. Dendritic cells 
deficient in SOCS 1 are hypersensitive to interferon signaling and promote aberrant B-cell 
proliferation leading to the production of autoreactive T-cel1s [55, 56]. Silencing of 
SOCS 1 can enhance dendritic cell response and antigen presentation, this is beneficial for 
anti-tumor responses by enhancing cytotoxic t-cell responses [55-57] 
SOCS 1 also helps in signaling within the innate immune system. Many foreign 
proteins such as v-E7 and bacterial LPS strongly induce SOCSl [58,59]. SOCSl 
induction helps curtail the levels of inflammatory cytokines and chemokines secreted by 
activated antigen-presenting cells as weIl as negatively regulating LPS-induced 
macrophage activation. SOCS 1 deficient mice have been shown to be unable to form a 
tolerance to LPS which can be lethal to them in certain cases [60]. Tumor necrosis factor 
alpha (TNF-a) is also regulated by SOCSl, giving SOCSl another branch of control over 
inflammation responses, such as TNF -a induced apoptosis, and regulation of cells within 
the immune system [61]. 
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Regulation oftheimmune system is therefore dependant on SOCSI at many 
levels. SOCS 1 plays a central role in the development of T -cells as weil as their 
homeostasis. It also plays a role in reducing macrophage activation due to extemal 
stimuli and reduces dendritic cell activation and their ability to present antigens, thereby· 
inhibiting autoimmune responses. As weil SOCS 1 directly controls the levels of many 
inflammatory signaling pathways su ch as TNF-a giving it direct control over 
inflammation and innate immune responses. 
SOCS! acts through its SH2 domain 
SOCS 1 acts through multiple mechanisms to inhibit the activity of JAKs. There 
are multiple lines of evidence supporting different mechanisms, which make use of the 
different structural domains of SOCS 1. Such diversity of mechanisms may seem 
redundant but is perhaps necessary to ensure proper regulation of signaling cascades that 
control growth and proliferation as weil as many components of the immune system. It is 
also known that the different SOCS family member act through different mechanisms 
from each other. For example CIS inhibits cytokine signaling in a mechanism different 
from that of SOCS 1 and does not bind directly to the JAKs [36, 62]. 
One of the mechanisms through which SOCS 1 exerts control over JAKs is 
through direct binding to the autophosphorylation site through interactions with the JH 1 
domain of JAK2 and the SH2 domain of SOCS 1 [34, 63]. Once cytokines bind to their 
receptors they induce phosphorylation of JAK2 at YI 007, a critical step in JAK2 
activation [64]. Subsequent downstream JAK2 signaling in tum induces SOCSl, which 
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regulates the pathway in a negative feedback manner. SOCS I is able to bind to JAK2 
phosphorylated at YI 007 with a high affinity but does not bind to unphosphorylated 
JAK2 or JAK2 mutants which contain mutations in the JHI domain (K882D) [34, 63]. 
Mutational analysis of SOCS I has revealed 3 regions necessary for complete binding and 
inhibition of JAK2 [63]. In order for SOCS I to bind to Y 1007 of JAK2 the SH2 domain, 
specifically a phospho-tyrosine-binding residue Arg 105, and a stretch of twelve amino 
acids (l68-G79) immediately N-terminal to the SH2 subdomain, dubbed the extended 
SH2 subdomain, are both required. A second set of twelve amino acids just N-terminal 
before the extended SH2 subdomain (N 56-67) are required for SOCS I to bind to JH I 
with high affinity and are necessary to inhibit JAK2 signaling. This region has been 
named the kinase inhibitory region (KIR). 
The extended SH2 subdomain contains three aminoacid residues 168, L 75 and 
G79, which are highly conserved throughout the SOCS family and appear at the same 
position relative to the SH2 domain of STATs as weIl. Similarity between the SH2 
domains of SOCS and ST A T family members may be important in SOCS I inhibition of 
JAK/STAT signaling as perhaps SOCS I could compete directly with STATs for binding 
sites with JAKs to reduce ST AT signaling. Mutating these conserved residues in (l68E 
and L75E) is enough to prevent the interaction between SOCSI and JHI and YI007 as 
weIl as reduce EPO-dependant ST A T5 signaling. Crystal structures of ST A T molecules 
show these conserved residues are involved in phospho-tyrosine binding in the SH2 
domain [65]. 
The Kinase inhibitory region is not important to binding to YI 007 but is essential 
for inhibition of JAK2 signaling and mutations to the region greatly hamper JHI binding 
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[63]. Mutations to individual amino acids in the region prevented SOCSI from inhibiting 
EPO-dependent ST A T5 signaling. Furthermore eight of the twelve amino acids are also 
present in SOCS3, which can also bind JH1 domains and inhibits the JAKs, further 
implying their importance in SOCS/JAK interactions [63, 66]. Among these conserved 
amino acids were F56, F59, D64 and Y65. Mutations to these residues in particular 
greatly hampered SOCS 1 from binding to JH1. Mutations to F59 showed the greatest 
effect suggesting it is perhaps the more critical residue [63]. 
The current mechanism for SOCS 1 interaction with JAK2 involves the SH2 of 
SOCS1 recognizing the phosphorylated Y1007 of JAK2. The c1assical SH2 domain is 
involved in binding to this region. The extended SH2 subdomain aids in further binding 
to JAK2. Binding to Y 1007 allows the KIR to bind to the JH1 with high affinity and 
disrupt Jak2 signaling. 
A 12 mer synthetic tyrosine kinase inhibitor peptide (Tkip) is able to mimic 
SOCS 1 by also inhibiting JAK2 signaling through binding of the autophosphorylation 
site [67]. Tkip is able to bind to JAK2 at YI 007 with a higher affinity than SOCS 1 and 
can bind to unphosphorylated JAK2 as weIl. Its binding to JAK2 is able to suppress IFN-
y activity, su ch as the upregulation ofMHC Class 1 molecules, induction of growth arrest, 
and EGFR autophosphorylation. Tkip actually acts much like the KIR region of SOCS 1 
[68]. By acting in a mechanism very similar to that ofSOCS1 Tkip is also able to inhibit 
constitutive ST A T3 and IL-6 activated ST A T3 in prostate cancer cells (LN CaP and 
DU145) [69]. Injecting mice with Tkip also reduces allergic responses by inhibiting 
overactive cytokine signaling [70]. 
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SOCS! as an E3 Ligase 
Another mechanism commonly used to control cellular signaling is the 
degradation of cellular receptors or other proteins involved in the cascade. Targeting of 
specifie proteins for degradation is a tightly controlled pro cess that requires complexes of 
enzymes working in unison. One of the better known pathways to protein degradation is 
the ubiquitin-proteasome pathway, which uses long chains ofubiquitin molecules to mark 
proteins for degradation [71]. Degradation is a two-step process. The first step requires 
the target protein to be covalently flagged with a long chain ofubiquitin, usually 
accomplished by a complex ofproteins. The second step is the actual degradation of the 
protein by the 26 proteasome. The actual attachment of ubiquitin to a target substrate is a 
three-step process and involves many proteins. The first is an El activating enzyme, 
which activates the ubiquitin molecules. Once activated an E2 ubiquitin carrier or 
ubiquitin conjugating enzyme (UBe), of which there are several, facilitates the transfer of 
the activated ubiquitin from the El to one of the E3 protein ligases. The substrate usually 
contains specifie sequences to ensure proper and specifie binding to the E3 ligase. The E3 
ligase is responsible for completing the process and creating the covalent bond between 
the ubiquitin and the target protein. Usually, the first moiety is attached to a NH2 group 
on a lysine residue, generating an isopeptide bond. Once the first moiety is attached the 
rest can attach to the proceeding moiety via its Lys48 residue. This allows the formation 
of a long poly-ubiquitin chain that serves as a flag, marking the prote in for later 
degradation by the 26S proteasome or lysosome. The number of E3 ligases are unknown 
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as many more proteins and/or protein complexes that have E3 ligase activity are still 
being discovered. 
Though the SH2 domain of SOCS 1 is responsible for binding to Jak2, it alone is 
not enough to inhibit JAK signaling [34]. A mutant copy ofSOCS1 lacking both C- and 
N- terminal domains also has no inhibitory affects on cytokine signaling demonstrated by 
its inability to inhibit c-fos activation by IL-2 or IL-3, which suggests that one or both of 
these domains is necessary for complete SOCS 1 activity. The C-terminus of SOCS l, like 
aIl SOCS family members, contains a domain known as the SOCS box [33, 34, 37, 39, 
72-76]. The SOCS box was once thought to be a unique domain to SOCS family 
members but has since been shown to be present in the C-terminal of a variety of 
different protein families inc1uding the Ras, WD-40 repeat, ankyrin repeat families and 
SPRY domain containing families [39, 77]. 
Within the SOCS box, there is a T/SLlMxxxC/SxxxVIL/I Elongin BC binding 
consensus sequence named the BC Box [77]. Elongin BC is a heterodimer protein 
complex made up of the ubiquitin like Elongin B, and Elongin C, a protein that resembles 
the adaptor protein Skp in sequence [78, 79]. Elongin BC was first shown to be an 
activator of the RNA Pol II elongation factor A (Elongin A) [80]. It has since been shown 
to also take part in the von Hippel-Lindau tumor suppressor complex (VHL) [81]. 
Mutations within, or deletions of the consensus sequence render Elongin A and VHL 
unable to bind Elongin BC [81-83]. Elongin BC is much more abundant in the cell than 
either Elongin A or VHL, which means it must have other activity or possible binding 
partners unrelated to the two [77]. It is now known that the Elongin BC complex can bind 
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not just SOCS l, but the BC box of ail proteins containing a SOCS box and that deletions 
or point mutations of the BC box inhibit the interaction [76, 77]. 
Endogenous levels ofElongin Band C can be immunoprecipitated from the 
1ysates of cells stimulated with interferon and IL-6 against antibodies for the C- and N-
tenninals of SOCS l, proving that this is a physiological interaction [77]. As well 
expressed Elongin Band C can be can be immunoprecipitated with antibodies against 
JAK2 and SOCS 1 in cells co-expressing JAK2 and SOCS 1. This Proves that Elongin BC 
is part of the SOCS 1 complex that binds to JAK2 and inhibits its signaling. Only a fonn 
of SOCS 1 with an intact BC box is capable of making the Elongin BC-JAK2 complex, 
although mutations in the BC Box do not disrupt SOCS 1-JAK2 binding. 
The VHL tumor suppressor acts as an active E3 1igase [84]. In this complex 
Elongin BC acts as an adaptor to link VHL to a Cullin and a RIN G finger-containing 
protein (Rbx). The cullins are a family ofproteins that assemble with an Rbx molecule to 
fonn a module capable of catalyzing the transfer of ubiquitin from an E2 ubiquitin 
conjugating enzyme to the target substrate [85, 86]. There are currently five known cullin 
members in mammals (CuI1-5) [87]. The VHL protein acts as a subunit of a multi-protein 
complex able to recognize substrates for ubiquitination [84]. The VHL tumor suppressor 
shows similarity to the SKP-Cul1-F-box E3 ligases (SCF), and both show sorne similarity 
to an Elongin BC-CuI2-S0CS 1 complex. SOCS 1 also binds to Elongin BC, Elongin B is 
an ubiquitin like molecule, and Elongin C shares sequence similarity to the adaptor 
protein SKP1 [78, 79]. The F- box is a similar domain to the SOCS box. Studies into 
SOCS 1 showed that it too was able to bind to a Cullin/Rbx module [88]. This Elongin 
B/C-CuI2-S0CS 1 complex is capable of fonning GST -polyubiquitin chains by the E2 
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GST-ubiquitin conjugating enzyme Ubc5 when ATP, El activating enzyme Uba1 and 
GST-ubiquitinK48R are present, proving it acts as an active E3 ligase. The crystallized 
structures of a similar complex involving SOCS2 also defined an E3 ligase [75]. As weIl 
SOCS3 also forms such a complex, and upon activation with IL-6 sees its protein 
expression peak within 60 minutes only to be near depleted by 120 minutes [76]. This 
drop off in SOCS3 levels is aboli shed by treatment with proteosomal inhibitors such as 
LLnL. This suggests that SOCS proteins form active E3 ligases that play a role in their 
subsequent degradation after induction. 
The specificity of the cullin binding is said to be due to a small stretch of amino 
acids located at the C-terminal of the SOCS box known as the Cul box [89]. Differences 
in the Cul box between VHL and SOCS family members lead VHL to specifically bind to 
endogenous Cul2-Rbx1 while SOCS-box proteins bind to endogenous CuI5-Rbx2. These 
differences allow VHL and SOCS family members to be grouped accordingly according 
to their Cul Box. VHL has a Cul2 box while the members of the SOCS family ofproteins 
contain a Cul5 box; the y bind to endogenous Cul5-Rbx2 and not CuI2-Rbx1. 
A specific conserved amino acid sequence of LPxP within the Cul5 box appears 
necessary for Cul5 binding as mutating it abolishes it. While aIl SOCS members have a 
Cul5 box, SOCS1 oddly has an incompletely conserved Cul5 box. The Cul box of 
SOCS 1 contains the amino acid sequence IPLN instead of LPxP; this leads SOCS 1 to 
bind to CuI2-Rbx1, not CuI5-Rbx2, making it an exception within the SOCS family as 
the only member to do so. Changes in Cul5 expression cause no change in the 
degradation ofVHL target substrate HIF-2a, however reducing Cul2 expression by usage 
of shRNA cause increases of HIF -2a. This suggests that each Cul member has a distinct 
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purpose or possibly has the ability to recognize different substrates. Ifthis is the case 
there could be sorne unique function conferred upon SOCS 1 as the only SOCS member 
that binds to Cu12. 
There is plenty of evidence to suggest that the mechanism by which SOCS 
proteins inhibit cytokines lies in their ability to form ECS E3 ligases. SOCS 1 localizes to 
the microtubule organizing complex that is associated with the 20 S proteasome itself in a 
manner dependent on the SH2 domain [90]. SOCS 1 also binds directly to the microtubule 
organizing complex (MTOC). Such a direct link to the proteasome suggests SOCS 1 may 
help localize targets to the proteasome for degradation. SOCS 1 does in fact cause JAK 1 
and VAV1 to localize to the MTOC and MTOC-associated 20S proteasome. 
Many studies have suggested that SOCS 1 directly targets proteins for 
degradation. SOCS 1 was shown to bind to the N- terminus of the guanine nucleotide 
exchange factor V AV, and reduce the formation of V AV -induced foci in NIH 3T3 cells 
[91]. SOCS1 also diminished the levels ofVAV within NIH 3T3 and COS celllines, and 
was ultimately found to induce ubiquitination ofVAV and onco-VAV. IFN-y induces 
expression of SOCS 1 and leads to a degradation of the viral oncogene E7 in HeLa and 
CaSki tumor lines [59]. E7 mRNA levels remain the same when SOCS 1 al one is 
expressed in these cells though E7 protein levels are diminished. SOCS 1 co-Iocalizes 
with E7 in the nucleus and can immunopreciptate with E7, suggesting a physical 
interaction. This interaction is dependent on the SOCS Box, but is uninterrupted by 
mutations of the SH2 domain. Like the interaction of SOCS 1 and VAY, tyrosine 
phosphorylation does not seem to play a role. SOCS 1 is also seen to promote 
ubiquitination of the viral oncogene E7 upon interaction and inhibits HPV -E7 mediated 
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transfonnation by leading to E7 degradation. JAK kinases su ch as JAK2 are sometimes 
involved in oncogenic fusions, su ch as the fusion protein TEL-JAK2 [74]. In Ba/F3 cells 
transfonned with TEL-JAK2 expression of SOCS 1 or induction of SOCS 1 by treatment 
oflL-3leads to apoptosis. This response is not seen however in Ba/F3 cells transfonned 
with p21 0 Bcr-Abl, showing SOCS 1 activity to be specific to JAKs. SOCS 1 mutants 
lacking the SOCS box cannot suppress the growth ofTEL-JAK2 cells, despite the SOCS 
box not being necessary to bind to JAK2, suggesting that the SOCS box still plays a role 
in inhibition of JAKs [74, 92]. In 293 cells fulllength, WT SOCS 1 can reduce the levels 
of TEL-JAK2 and suppress TEL-JAK2 activation of ST A Ts. Treatment of proteasome 
inhibitors MG 132 and lactacystin protected TEL-JAK2 from SOCS 1 induced 
degradation, suggesting it is proteasome dependent. Further studies showed that 
phosphorylation of the JHl domain led to binding with SOCSI and led to de gradation of 
JAK2 preceded by SOCS 1 induced ubiquitination of TEL-JAK2. The SH2 domain of 
SOCS 1 is necessary for degradation ofTEL-JAK2. The SOCS box domain can be 
replaced with that of the protein CIS, but not the SOCS3 SOCS box. SOCS3 binds and 
inhibits TEL-JAK2, but does not induce its degradation, this is odd as both SOCS3 and 
CIS contain a different CulS box from SOCSI [66,89]. A dominant negative Cul-2 
inhibits the Tel-JAK2 degradation, suggesting SOCS 1 induced degradation must work in 
an E3 ligase manner. 
SOCS 1 also acts in the insulin signaling pathway and degrades insulin receptor 
substrates (lRS). In HEK293 cells, SOCS 1 associates with IRS 1 and IRS2 via 
interactions that are significantly increased in response to insulin signaling. SOCS2 and 
SOCS3 were also found to interact with IRSI and IRS2. Interactions between SOCSI and 
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IRS leads to subsequent falls in the levels ofIRS 1 and IRS2 in HEK293, MCF7 breast 
cancer cells and ETE-LI adipocytes. Induction of SOCS 1 by treatment with 
proinflammatory cytokines such as IL-6, TNFa, and IFN-y also led to reductions in 
levels of IRS 1 and IRS2. Expression of SOCS 1 in the liver of mice via adenovirus 
infection causes IRS 1 and IRS2 levels to fall until the infection is no longer detectable at 
which point IRS levels retum to normal. A SOCS 1 mutant missing the SOCS box is 
unable to regulate the same control over IRS 112 as can wild type SOCS 1. Mutations to 
key residues of the BC box cause a decrease in degradation of IRS but do not prevent 
SOCS 1 binding. This led Rui et al. to search for ubiquitination ofIRS 112. They found 
that SOCS 1 was indeed able to lead to ubiquitination ofIRS 112, although this could be 
prevented with treatment of MG 132 or lactcystin. 
Colony formation induced by the granulocyte-colony stimulating factor, G-CSF, 
as weIl as its activation of ST A T3 and ST A T5, are also suppressed by SOCS 1 and 
SOCS3. However, both ~SOCS Box mutants of SOCS 1 and SOCS3 fail to cause any 
changes to colony formation or ST A T activation in response to G-CSF [94]. This also 
suggests a possible role of SOCS box mediated degradation of G-CSF or its downstream 
targets as weIl. Stabilization of phospho-ST AT5 by proteasomal inhibitors supports this 
model. The Apoptosis signal-regulating kinase 1 (ASK 1) is also a target of SOCS 1 
induced degradation [95]. ASK 1 binds to SOCS 1 through its SH2 domain and is both 
ubiquitinated and degraded. It is known that TNF signaling stabilizes ASKI levels and 
prevents degradation while SOCS 1 acts as a negative regulator of TNF and promotes 
ASK 1 degradation. 
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These results have shown two powerful properties of SOCS 1. The first is to act on 
target substrates by fonning an E3 ligase with Elongin BC and a Cul-Rbx subunit in the 
SOCS box domain [76, 77, 88, 89]. It suggests the SH2 domain is used to recognize 
substrates which it than marks for proteosomal dependent degradation [59, 74, 91, 96]. 
Localization with the MTOC associated with the 20S proteasome only strengthens this 
argument [90]. It also shows another important property of SOCS l, the property of a 
tumor suppressor. It has already been established that SOCS 1 inhibits the JAK, a family 
of tyrosine kinases. Receptor tyrosine kinases are implicated in many cancers as 
mutations which confer constitutive activity to them cause an over stimulation in many 
signaling cascades that promote growth and proliferation. However the results mentioned . 
above also show SOCS1 's ability to directly target other oncogenes su ch as EP7, onco-
V A V and the TEL-JAK2 fusion protein and directly lead to their destruction by targeting 
them for proteosomal degradation. 
SOCS! in Cancer 
Receptor tyrosine kinases have been identified as being proto-oncogenes. The 
JAKs as weIl can serve as oncogenes should their signaling go astray, or should they 
become involved in fusion proteins. SOCS 1 meanwhile demonstrates tumor suppressor 
properties [97]. Tumor suppressors are often inactivated in a variety of cancers either 
through gene silencing or mutations that encode a non-functioning protein. SOCS1 can 
actually prevent transformation of Ba/F3 ceIllines caused by Tel-JAK2 by inhibiting 
JAK2 and leading to its degradation [92]. Gene methylation of CpG islands and other 
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epigenetic modifications are seen in a variety of cancers, this often leads to silencing of 
tumor suppressor genes. SOCS1 methylation was first demonstrated in HCC cell lines 
(65%) [98]. Several groups have since repeated similar studiesshowing a high level of 
SOCS1 methylation in HCC, corresponding to a low level of expression and 
accompanied with constitutive JAK2 activation [99-102]. Since th en it has been shown 
that SOCS1 is methylated in a variety of cancers. In 2003, it was shown that over halfthe 
patients sampled (53%) with newly diagnosed acute myeloid leukemia (AML) showed 
methylation of the promoter region of SOCS1 [103]. Multiple myeloma ceIllines such as 
the IL-6 dependant XG 1 and U266 lines show a low level of SOCS1 expression even in 
the presence ofIL-6 compared to controllines [104]. These ceIllines showed high levels 
of ST A T3 phosphorylation and a higher sensitivity to a chemical JAK inhibitor, AG490, 
which induced apoptosis. Samples taken from primary tumors of multiple myeloma also 
confirmed the results shown in cell culture as one study showed 62.9% of patients 
sampled to have SOCS1 methylation. This is also confirmed by the fact that SOCS 1 
deficient mice die within 3-4 days due to a lymphoma [41,42]. Many human pancreatic 
cancers have also shown reductions in expression of SOCS1 [105]. This usually 
correlated with a methylation of the 5' promoter region for SOCS1. While one group 
showed methylation of the SOCS1 promoter region in tumor samples, they found no 
mutations to markers within SOCS1. Breast and ovarian cancer displayed SOCS1 
methylation as weIl but showed a pattern of di fferenti al hypermethylation between other 
members of the SOCS family [106]. SOCS1 was found to be hypermethylated in 4 out of 
6 studied ovarian cancer cell lines and 8 out of Il breast cancer lines. Wh en actual 
tumors were studied, 23% of ovarian cancers had hypermethylated SOCS1 CpG islands, 
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while only 9% of the breast cancers showed the same result. Cells from the colorectal 
cancer line Hep3B, which have methylated DNA, also do not express SOCS] [107]. Also, 
SOCS 1 deficient mice showed a higher rate of developing tumors within their colon due 
to over inflammation in response to uninhibited IFN-y/Stat1 signaling [108]. Other 
groups have shown that SOCS 1 hypermethylation and subsequent loss of SOCS 1 
expression confers growth-promoting effects in pancreatic cancers su ch as pancreatic 
ductal adenocarcinomas and intraductal papillary mucinous neoplasms [109]. Silencing 
of SOCS] can occur due to loss ofheterozygosity (LOH) and can lead to an increase of 
carcinogenesis in mice livers [110]. Hypermethylation of SOCS] in ail these cancers 
leads to a large reduction in expression, this effectively allows for constitutive 
JAK/ST AT signaling. Constitutive signaling of both the Janus kinases and ST A T 
molecules has been largely linked to the formation of cancers in the past [111]. Silencing 
of SOCS] in these tumors can often be reversed by introducing agents that reverse DNA 
methylation, su ch as 5-azadeoxycytidine (5-aza-dC), mimic SOCS1 activity (Tkip), or 
directly inhibit the JAKs [69, 104, 106, 112]. Restoration of SOCS] expression or 
overexpression of SOCS] in these cancers often leads to growth inhibition or induction 
apoptosis. SOCS] mutations have been found in a significant number of tumors from 
Hodgkin, Reed-Stemberg, Hodgkin and classical Hodgkin tumors as weil as in primary 
mediastinal B-celllymphomas [113]. Mutations can range from out of frame mutations 
which lead to premature stop codons cutting off the SOCS box domain, to deletions in 
amino acids of the SH2 domain. These mutations lead to 10ss offunction of SOCS] and 
allow JAK2 signaling to persist, eventually resulting in an accumulation of active 
phospho-ST A T5 in the nucleus. In primary mediastinal B-celllymphoma (PMBL) cell 
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lines, MedB-1 and KaJ-pas11 06P, biallelic mutations to the coding region of SOCS 1 
allow JAK2/STAT5 signaling to go unchecked [114,115]. In this cancer, JAK2 remains 
constitutively active although it shows only a normal physiologicallevel of expression. 
Instead JAK2 degradation is greatly impaired, hence the JAK2/ST A T5 signaling cascade 
is allowed to persist. Overexpressing SOCS 1 in MedB-1 celllines with this mutation 
leads to growth inhibition [114]. 
Our 1ab focuses on the study of premature senescence and growth arrest. 
Premature senescence is a permanent cell cycle withdrawl that can act as a tumor 
suppressor mechanism [116-118]. Senescence can be induced in response to oncogenic 
stress as a barrier to transformation. Previously, our 1ab demonstrated that a constitutively 
activated form ofSTAT5 (STAT5A1 *6) can induce premature senescence [119]. SOCS1 
is highly upregulated in STAT5 senescent cells, implicating its involvement in 
senescence. Other SOCS1 activators such as ~-IFN can also induce senescence [120]. 
Members of our lab have demonstrated that overexpression of SOCS1 in the IMR90 
. fibroblast line Induces premature senescence. It is established that SOCS 1 is able to 
induce a growth arrest in cells. However, the mechanisms by which it acts are completely 
unknown. SOCS 1 can indu ce p53 and SOCS 1 induced senescence in the IMR90 cellline 
was shown to be p53 dependent. SOCS 1 has the ability to bind to and inhibit JAKs and 
can form E3 ligases. Whether either ofthese functions is necessary for the induction of 
senescence or growth arrest is unknown. AIso, the role of the different domains of 
SOCS 1 is unknown at this time. 
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Regulation of SOCSl 
The mechanisms by which SOCS 1 is regulated are not weil known. While many 
different stimuli for SOCS 1 induction are weil known and documented, the negative 
regulation of SOCS 1 remains for the most part a mystery. Tt is known that SOCS 1 can be 
targeted by other SOCS family proteins for degradation [121]. SOCS2 has been shown to 
have the ability to bind and inhibit SOCS 1 by targeting it for proteosomal degradation. 
Both SOCS6 and SOCS7 were later shown to have the ability to interact with aIl other 
SOCS molecules. Other reports suggest that SOCSI leads to its own auto degradation and 
that binding to the machinery of its E3 ligase such as the Elongin BIC complex lead to 
reductions in SOCS1 protein stability [76, 122]. However other reports have shown it is 
necessary to have binding of SOCS 1 to the Elongin BIC to promote stability and that 
interruptions in binding lead to proteasomal degradation [77, 123, 124]. The 
interconnecting web of a family of SOCS proteins, each capable offorming active E3 
ligases acting on one another and each with the ability to potentially self-regulate makes 
the exact mechanisms of regulation by means of how SOCS 1 is regulated by proteasomal 
degradation hard to elucidate, especially considering how little is known about the 
majority of the other SOCS family members. Other groups have pointed to protein 
kinases that may regulate SOCS 1. The Pim family of prote in kinases was shown to 
phosphorylate SOCSl which 1eads to stabilization ofprotein levels [122]. It is possible 
that SOCS 1 undergoes other modifications which are used to regulate it at the protein 
level, including phosphorylation by other kinases, however as ofyet the se mechanisms 
remain mostly unknown. 
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Materials and methods: 
Cel! culture 
AlI IMR90 primary ceIllines and U20S sarcoma ceIllines were cultured in Dulbecco's 
Modified Eagle Media (DMEM) (GIBCO) supplemented with 10 % FBS (GIBCO) and 
1 % Penicillin G-streptomycin sulfate (GIBCO). 
Retroviral vectors and gene transfer 
The foIlowing retroviral vectors were used, pLPC and its derivatives expressing SOCS1, 
SOCS3, SOCS5, SOCS6, SOCS1 &Jax, SOCS1 &JC, SOCS1 ,dCul, SOCS1 LW 198 and 
SOCS1 N198P as weIl as the retroviral vector in pBABE and its derivatives hRAS and 
STA T5A 1 *6. Phoenix ceIls were plated to a density of2.5x104 ceIls / ml in a 10 mm 
culture plate (Coming) (l0 ml total volume) and transfected with retroviral vectors (20 
/lg) and treated with 200 /lI of 5 mg/ml sodium butyrate the next day. Medium was 
changed 12 hours after sodium butyrate addition. 12 hours after the medium was changed 
and retro viral soups were coIlected and supplemented with 10% FBS and 4 mg/ml 
polybrene. The supplemented soups were immediately added to primary ceIls which had 
been previously plated to a density of 8.0 x 105 cells / ml in 10 cm culture plates 
(Coming). Cells were treated with new retroviral soups every 6 hours for a total of 3 
infections. Infected cells were selected in puromycin 2.5 /lg/ml (Bioshop) for 2 days. 
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SA fJ-Gal activity 
IMR90 cells were infected as described above. Cells were given 3 days recovery period 
after selection and plated at a density of 2.5 xl 05 cells / ml 6 days post selection. Cells 
were than incubated in 5-bromo-4-chloro-3-indolyl-~-D-galctopyranoside (X-Gal) at pH 
6.2 at 37°C until the negative control showed approximately 10% positive staining. The 
percentage of cells expressing SA-~-Gal was quantified by inspecting 100 cells per 10 
mm plate three times. 
Immunojluorescence microscopy 
IMR90 cells were plated on cover slips in a 6-well plate at a density of2.5x104 cells / ml 
and fixed using 4% paraforrnaldehyde (Fisher Scientific) in PBS for 15 minutes at room 
temperature. Cells were washed several times in PBS and perrneabilized using 0.2% 
Triton X-100 (Fisher Scientific) in PBS with 3% bovine serum albumin (BSA) on ice for 
5 minutes. Cells were than washed again several times with PBS/BSA and than treated 
with the primary antibody, anti-PML (Rabbit) prepared by Marie-France Gaumont-
Leclerc for 1 hour at room temperature in a humidified chamber. After three more 
PBS/BSA washings cells were stained with Alexa-Flora Red, anti-rabbit secondary 
antibody (l :2000) (Molecular Probes) for 1 hour in a humidified chamber. Cells were 
than washed several times with PBS/BSA and counterstained with 4,6-diamidino-2-
phenylindole (DAPI) at a concentration of 0.1 ~g/ml in PBSIBSA. Fluorescence 
microscopy was perforrned using an inverse fluorescence microscope (Nikon TE2000) 
and the Metamorph software (Molecular Devices). Images were prepared using 
Metamorph and Canvas X (Deneba). 
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SOCS1 mutagenesis 
The SOCS1 L1Box construct had already been prepared by Vivianne Calabresse. The rest 
of the SOCS1 mutants were made using PCR techniques. Ali reactions were performed in 
a Biometra T-gradient PCR Machine. Reactions were performed in 100 /lI total volume 
using 50 ng ofpLPC SOCS] as a template, 200 /lm dNTP, 50 !-lM ofboth primers, and 
5% DMSO and Deep Vent Polymerase O'Jew England Biolabs) and it's Thermopol 
Buffer O'Jew England Biolabs). SOCS1,(jCul was created using a PCR using a sense 
primer (referred to as SOCS 1 sense primer) of 
5 'GCGAA TTCTGA TGGTA GCACGCAACCA GGTG3 ' and an antisense primer 
5 'GCGGGCTCGAGTCAGTTCTCGCGACCCACGGC3' that introduced a premature 
stop codon before the Cul Box. 
SOCS L1BC was created using a two step process. First two small fragments were 
made. Fragment A was created using the SOCS 1 sense primer as used for SOCS1,(jCul 
and an anti-sense fragment that started at the beginning of the BC Box and contained a 15 
bp overlap for fragment B, 5 'ACCCACGGCGGC CACCCGCACGCGGCGCTG3 '. 
Fragment B was created using a sense primer that had a ] 5 bp overlap to the tail of 
Fragment A and started after the BC Box, 
5 'CAGCGCCGCGTGCGGGTGGCCGCCGTGGGT3 ' and a normal antisense primer for 
SOCS1, 5 'CGCTCGA GTTCA GA TCTGGAAGGGGAAGGA3 '. The two fragments were 
than used as a template for a reaction using the normal SOCS 1 sense and antisense 
pnmers. 
SOCS1 LfN198 and SOCS1 N198P were made in a similar fashion. First a fragment 
was made using the aforementioned SOCS 1 sense primer and an antisense primer 
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introducing a deletion of the 198P residue, 5 'GTCACGGAGTACCGGAAGAGG 
GATGCGCGC3' this fragment was not fulliength SOCSl. A second fragment was made 
using a forward primer that contained a 15 bp overlap to the first fragment and introduced 
a sense strand deletion mutation to the 198 P residue, 
5 'GCGCGCATCCCTCTTCCGGTACTCCGTGAC3' and an antisense primer that started 
after the SOCS 1 insert in the pLPC vector back bone, to produce a larger in sert th an 100 
bp to facilitate cloning, 5 'CAGCTG TTCCATCTGTTCTTGGGC3 '. The two fragments 
were than used as template for a PCR reaction using the normal SOCS 1 sense primer and 
a second SOCSI antÏsense primer (as the first did not work well with this reaction) 
5 'GGGCCTCGA GTCA GA TCTGGA AGGGGAAGGA3' to give a fulIlength SOCSI 
product with the ~N198 mutation. The N198P mutant was made in similar fashion using 
the SOCS 1 sense primer and aN 198P antisense primer 
5 'GTCACGGAGTACCGGGGGAAGAGGGATGCGCGC3 J. Fragment B was generated 
using a sense primer of 5 'GCGCGCA TCCCTCTTCCCCCGGTA CTCCGTGAC3 ' and the 
pLPC antisense primer mentioned above. AlI mutants were sequenced at l'Institut de 
Recherche en Immunologie et en Cancérologie (IRIC) to make sure mutants were in the 
right places and that no other errors were introduced by the PCR process. 
Colonyassays 
U20S cells were transfected with 15 )lg ofDNA using the calcium phosphate method. 
Transfected cells were selected in puromycin l)lg 1 ml for 6 days. After which cells were 
given a 2 day recovery period for colonies to grow. Cells were then stained in 0.5 % 
Crystal violet to show colony formation. Cells were de-stained using 10% Acetic acid. 
30 
100 !lI of each sample was loaded to a 96 weIl plate and measured for absorbance at the 
960 nm wavelength in a plate reader. Values were plotted on a bar graph and normalized 
to the control to show relative differences in growth. Standard error represents 1 standard 
deviation from the mean value. 
Prote in analysis 
Immunoblots were preformed using whole-celllysates obtained by first making cell 
pellets and than boiling them in Laemmli sample buffer. Samples of20 !lg ofprotein 
were resolved in SDS-polyacrylamide gel electrophoresis and transferred using the wet-
transfer method to Immobilion-P membranes (Millipore). Antibodies used in the 
immunoblots inc1ude anti-SOCS 1 (4H 1; 1: 1 000 Upstate), anti-p53 (catalog number 9282 
1:1000 Cell Signaling Technology), anti-PS-15p53 (catalog number 9284 1:1000 Cell 
Signaling Technology), anti-p21 (catalog number 2949 1:1000 Cell Signaling 
Technology), anti-RB (C-19, 1:250 Santa Cruz Biotechnology), anti-Mdm2 (2AI0; 
1 :250; donated by A. Levine), anti-Tubulin (B-5-1-2; 1 :2,000; Sigma). Western blot . 
assays were performed using ECL detection (Amersham) or Lumilight detection system 
(Roche Applied Science). 
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Results: 
We were interested in exploring the full extent and mechanisms of SOCS 1-
mediated growth arrest. First, we explored SOCS 1 growth arrest in primary cells. When 
infected into IMR90 fibroblasts SOCS 1 induces a permanent cell cycle aire st known as 
premature senescence. Senescent SOCS1 cells show a larger, flatter morphology and 
stain positive for the senescence associated ~-galactosidase akin to oncogenes such as 
RAS and STAT5A1 *6 (Figure lA) [125]. As well these cells show accumulation ofPML 
bodies within the nucleus (Figure lB). Accumulation ofPML bodies in the nucleus is 
often used as a marker of senescence [125]. 
Since premature senescence is a tumor suppressor pro gram it was interesting to 
see the effects of SOCS 1 on the growth of cancer cells directly. The sarcoma ceIlline 
U20S was transfected with SOCS1 and an empty vector. As shown in Figure 2 SOCS1 
expression abolishes the ability ofU20S cells to form colonies and greatly hinders their 
growth. Hence SOCS 1 is also able to lead growth arrest within tumor ceIllines as weIl as 
inducing permanent cell cycle arrest in primary cells. 
Members of the SOCS family ofproteins exist in similar pairs, SOCS1 
and SOCS3 for example are more similar to each other than to other family members 
[38]. Sorne other SOCS members such as SOCS3 have also been demonstrated to play 
roles within a variety of cancers as weIl [106]. We wanted to see the effects of other 
SOCS family members on growth arrest so we repeated the colony assay in U20S using 
SOCS3, SOCS5, CIS4/S0CS6 as weIl. As demonstrated above SOCS1 completely 
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abolishes the ability ofU20S cells to fonn colonies as the SOCS1 transfected cells didn't 
fonn colonies as did the control plate (Figure 3B). 
Although very similar in sequence to SOCS1, SOCS3 does not inhibit colony 
fonnation in the U20S cell line. Though the number of relative colonies is slightly lower 
than that of the control plate, it is significantly higher than that of the SOCS1 plate 
(Figure 3B). Surprisingly, SOCS5 over-expression actually causes a near two fold 
increase in the number of colonies fonned (Figure 3B). This result was repeatable and 
suggests SOCS5 may actually play the role of an oncogene. The full role of SOCS5 is 
largely unknown though it may function by actually interacting with the activity of other 
SOCS moJecules, as sorne crosstalk and interference between SOCS family members has 
been previously shown. [121]. SOCS6 was the only other member tested that showed the 
ability to prevent colony fonnation that was significantly similar to SOCS1 (Figure 3A & 
3B). When tested in primary cells however, SOCS6 is unable to induce premature 
senescence (Figure 4). This suggests that SOCS6 maybe capable ofinducing growth 
arrest, but unable to induce a pennanent cell cycle arrest such as SOCS 1 through 
induction of the senescence program.SOCS2 and SOCS7 as weil as CIS constructs were 
unavailable at this time. 
Many roles of SOCS 1 are dependent on its SOCS box domain and its ability to 
fonn an active E3 ligase [73, 74, 91, 93]. E3 ligase activity ofSOCS1 requires an intact 
SOCS box to assemble the E3 ligase machinery. We wanted to investigate whether 
SOCS1 induced growth arrest was dependent on the SOCS Box as weIl. We made a 
series of SOCS box mutant lacking both the BC and Cul box subdomains, labelled as 
SOCS1 LillC and SOCS1 fjCul respectively. As weil a SOCS construct lacking the entire 
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SOCS box, SOCS1 Lillox, was donated to our lab and sub-cloned into a pLPC vector. 
These mutants were then transfected into U20S cells (Figure 5). 
Deletions of the entire SOCS box have only minor effects on SOCS1 induced 
growth arrest in U20S (Figure 5). This points to a possible role of SOCS 1 in growth 
arrest that independent of its SOCS box and its E3 ligase activity. SOCS1 constructs 
containing deletions of the BC and Cul box also show little effect on growth arrest 
(Figure 5). However these mutants provide no real infonnation to this regard as the levels 
of SOCS 1 in the cells are poorly expressed and cannot be detected through western blots 
(Figure 6A). 
Sorne studies have shown SOCS 1 can target itself for auto degradation or that 
binding to the Elongin BC complex is necessary for stability ofSOCSl [77,123,124]. 
To see ifthis is the case with our SOCS mutants we treated transfected U20S cells with 
MG 132, a proteasome inhibitor, before collecting extracts. In these cells SOCS 1 levels 
are greatly enhanced compared to that ofuntreated cells (Figure 6B). This indicates that 
SOCS 1 lacking functional BC box and Cul box domains are targeted for proteasomal 
degradation whereas it appears SOCS1 constructs lacking the entire SOCS box domain 
are not (Figure 6A & B). SOCS1 LillC and SOCS1 LJCUL mutants still retain parts of the 
SOCS box and possibly still able to present epitopes or potential binding sites for other 
E3 ligases (such as other SOCS molecules) to recognize them and mark them for 
degradation (Figure 7 A). The SOCS1 LJbox mutant lacks the entire SOCS box and may 
present no epitope and could be therefore protected from degradation (Figure 7B). 
It had previously been demonstrated in our lab that SOCS 1 induces the p53 
pathway in fibroblasts and that SOCS1 senescence was p53 dependent (Malette et. al 
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Unpublished). We wanted to see if SOCS 1 regulated p53 in a similar manner in U20S 
and to see if the SOCS box mutants had any effect on p53 activity. As was shown by 
other members of our lab in primary cells, SOCS1 expression does lead to an induction of 
p53 (Figure 6A). As well SOCS 1 expression lead to an increase in the level of 
phosphorylation at Serine 15 on p53 and an increase in the levels of p21 (Figure 6A). 
These results show activation of the p53 signaling pathway by SOCSI in U20S. The 
activation of p53 by SOCS 1 seems to be a general part of its activity in inducing growth 
arrest. The Rb pathway showed no activation by SOCS 1 indicating that SOCS1 growth 
arrest though p53 dependant, does not seem to engage the Rb pathway (Figure 6A). 
The transcription factor p53 is regulated by many E3 ligases, including MDM2, 
COPI and Pirh2 [126]. One possible mechanism by which p53 levels could be stabilized 
and increased is by degradation or inhibition ofMDM2, a negative regulator of p53. 
SOCS 1 does not lead to any changes in MDM2 levels meaning there must be another 
mechanism by which SOCS1 expression leads to increases in p53 levels (Figure 6A). The 
effects of SOCS 1 on COP 1 and Pirh2, other E3 ligases that regulate p53 were not tested. 
The SOCS1 mutants did not show any increases in p53, p53 serI 5 or p2I (Figure 
6A). However as mentioned before the SOCS1 L1BC and SOCS1 L1CUL mutants are 
poorly expressed thus we cannot interpret anything from their results (Figure 6A). The 
SOCS1 L1BOX is relatively stable however its failure to activate the p53 pathway suggests 
the SOCS box or subdomains within the SOCS .box could be required for p53 activation, 
though not necessarily in a manner dependent on E3 ligase activity. 
Since large domain mutations of SOCS 1 lead to instability of SOCS 1 we tried a 
different approach to determine the role of the SOCS box in SOCSI induced growth 
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arrest. Kamura et al. had previously shown that SOCS 1 shares a unique sequence in its 
Cul box that allows to it to bind to Cul2/Rbx 1 whereas aIl other SOCS family members 
bind to Cul5/Rbx2 complex (Figure 8). Specifically SOCS 1 has an Asparagine residue at 
position 198, whereas aIl other SOCS proteins have a proline. Using site directed 
mutagenesis we created two more SOCSI mutants, SOCSJ NJ98P and SOCSJ L1NJ98, 
containing specifie mutations to this sequence. These mutants change the IPLN sequence 
ofSOCSl to IPLP, which resembles the LPxP consensus site for Cu15 binding. Therefore 
these mutants should allow SOCS 1 to bind to Cu152/Rbx2 like aIl other members of the 
SOCS family, thus altering its usual E3 ligase activity. 
We again used the colony assay in U20S to study the effects ofthese mutants on 
cell growth. As seen in Figure 9 both mutants abolished the usual growth inhibition of 
SOCS1 (Figure 9A). While cells transfected with both of the Cul box mutants resembled 
those transfected with the control vector, the SOCSI ~N198 construct had the largest 
effect with a relative growth of 1.56 times that of the control (Figure 9B). The SOCS 1 
N198P mutant showed slightly less growth relative to the control (0.76) but mu ch more 
than SOCS 1 (Figure 9B). 
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Figure 1 SOCS l-induced senescence in the fibroblast line IMR90. (a) Cells were 
infected with a control vector pLPC, pL PC SOCS 1, or two positive controls pBABE 
STAT5Al *6 and pBABE RAS. Cells were fixed and stained 6 days post selection for 
senescence associated ~-galactosidase, (SA-~-gal). Differences in morphology of cells 
can be seen. Percentages of cells that stained positive after 2 counts of 100 cells in 2 
separate plates are labeled. (h) Immunodetection of PML bodies: cells were infected with 
a control vector, pLPC, pLPC SOCS 1 or the positive control pBABE ST A T5A 1 *6. Cells 
were plated to a density of 2.5x 1 04 cells / plate in a 6 weIl plate at 6 days post selection 
and fixed the day afteL PML was detected using an anti-PML antibody manufactured in 
our labo Nuclei were counterstained with DAPI. 
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Figure 2 SOCS 1 growth arrest in U20S cell line. Cells were transfected with a control 
vector pLPC or its derivative pLPC SOCS 1. After transfection cells were selected for 6 
days with puromycin followed by a 2 day recovery period for colonies to grow. Colonies 
were stained with 0.5% Crystal violet solution. 
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Figure 3 SOCSI growth arrest in U20S cellline. (a) Cells were transfected with a 
control vector pLPC or derivatives containing SOCS family members. After transfection, 
ceUs were selected for 6 days with puromycin followed by a 2 day recovery period for 
colonies to grow. Colonies were stained with 0.5% Crystal violet solution. Untransfected 
cells are demonstrated as a negative killing control. (b) Relative growth of cells when 
norrnalized to control vector, pLPC. CeHs stained with crystal violet were destained with 
10% glacial acetic acid. 2 100 ul volumes from each plate were transferred to a 96 weIl 
plate and measured for absorbance at 600 nm. A verages are obtained from 2 counts per 
plate from two plates of each condition. 
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Figure 4 SOCS6 fai1s to induce senescence in the fibroblast 1ine IMR90. Cells were 
infected with a control vector pLPC, pLPC SOCS 1, pLPC SOCS6 or the positive control 
pBABE RAS. Cells were fixed and stained 6 days post selection for senescence 
associated p-galactosidase, (SA-p-ga1). Differences in morphology of cells can be seen. 
Percentages of cells that stained positive after 2 counts of 100 cells in 2 separate plates 
are labeled. 
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Figure 5 SOCS 1 domain mutant affects on growth arrest in U20S cellline. Cells were 
transfected with a control vector pLPC or derivatives containing wild-type SOCS 1 or 
SOCS 1 domain mutants. After transfection cells were selected for 6 days with puromycin 
followed by a 2 day recovery period for colonies to grow. Colonies were stained with 
0.5% Crystal violet solution. 
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Figure 6 SOCS 1 domain mutant affects on cell cycle regulators. (a) U20S cells were 
transfected with a control vector pLPC or derivatives containing wild-type SOCS 1 or 
SOCS 1 domain mutants. Cell ex tracts were prepared from cells collected a day after 
transfection. 20flg of protein from total ceIllysate was used for SDS-PAGE gels and 
individual proteins were detected with immunoblotting using specific antibodies. (b) 
SOCS 1 domain mutants have low stability due to protein degradation. U20S cells were 
transfected as in (a) but treated with MG132 (+) or untreated (-) for 8 hrs before being 
collected for lysate preparation. Levels of SOCS 1 proteins were detected after 
immunoblotting with the 4Hl anti-SOCSI antibody (Upstate). A Ioading error occurred 
during preparation of the ~Cul box Iane so that the treated sample (+) was loaded before 
the untreated (-). In aIl other samples, treated samples follow untreated controls. 
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Figure 7 Depiction of SOCS 1 marked for degradation by polyubiquitin chains (a) Both 
SOCS 1 f..BC and SOCS 1 f..Cul present epitopes allowing them to be marked by other E3 
ligases, possibly other SOCS molecules. (b) SOCS 1 f..Box presents no epiptopes and is 
protected from degradation. 
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Figure 8 Clustal W alignment of SOCS 1 protein sequences. (a) Alignment of sequences 
from the SOCS Box domains of the SOCS family members. Cul box binding sequences 
are highlighted in yellow. (b) Alignment demonstrating changes in Cul box binding in 
SOCSI ~N198 and SOCSI N198P mutants. 
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Figure 9 Effects of Cul box binding mutants on growth arrest in U20S cells. (a) Cells 
were transfected with a control vector pLPC or SOCSI derivatives including wild-type 
SOCSl, SOCSI fJ.N198, SOCSI N198P and a SH2 domain mutant, SOCSI RI05E. After 
transfection cells were selected for 6 days with puromycin followed by a 2 day recovery 
period for colonies to grow. Colonies were stained with 0.5% Crystal violet solution. 
Untransfected cells are demonstrated as a negative killing control. (b) Relative growth of 
cells when normalized to control vector, pLPC. Cells stained with crystal violet were 
destained with 10% glacial acetic acid. 2 100 ul volumes from each plate were transferred 
to a 96 well plate and measured for absorbance at 600 nm. Averages are obtained from 2 
counts per plate from two plates of each condition. 
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Discussion: 
Senescence is a pennanent cell cycle arrest that protects cells against oncogenic 
transfonnation and has been linked to aging [116-118]. Senescence usually signaIs 
through the p53 or Rb pathway or both. The p53 protein is a transcription factor which 
regulates apoptosis and many of the genes involved in senescence [127]. It is mutated in 
over half of ail cancers and has been linked to aging. Retinoblastoma (Rb) protein is also 
highly mutated in a large number of cancers and exerts control over E2F responsive 
genes [128]. Premature senescence was first described in response to oncogenic RAS 
[129]. Since then other stimuli inc1uding DNA damage, over expression ofPML, 
oncogenes such as STAT5 and prolonged IFN-~ exposure have been shown to induce the 
senescence program [119, 120, 130]. SOCS1 is induced both by IFN-~ and STAT5 
hinting at its involvement in the senescence pro gram [131]. 
Here we show that overexpression of SOCS 1 in primary cells is able to induce a 
pennanent cell cycle arrest showing several senescent markers including accumulation of 
PML bodies and a high number of cells that stain positive for senescence associated ~­
galactosidase. PML bodies are foci that fonn in the nucleus of senescent cells and help 
recruit p53 to nuclear bodies [132, 133]. Furthennore SOCS 1 is able to directly inhibit 
the growth of cancer cell lines such as U20S. Inhibition of growth in U20S cells is 
accompanied by an induction in p53 and phosphorylation at serine 15 as well as an 
induction in its downstream target p21, indicating activation of the p53 pathway. This 
coincides with earlier reports in which SOCS 1 has been previously described as having 
tumor suppressor activity, as well as the numerous studies showing that SOCS is 
methylated in a variety of cancers [97,106]. Previously the tumor suppressor activity of 
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socs 1 has been credited by blocking transformation through inhibition of the 
JAK/STAT pathways. The involvement of SOCS1 in directly inducing growth arrest and 
cellular senescence independently of inhibition of JAKIStats, perhaps by acting directly 
on the p53 pathway is a novel concept explored in our labo 
Despite the fact that aIl SOCS molecules can inhibit JAKISTAT signaling, only 
SOCS 1 was shown to be able to induce both growth arrest in cancer celllines and cellular 
senescence in primary cells in our limited study. SOCS6 was able to induce growth arrest 
but failed to induce premature senescence. Even SOCS3, the most similar of SOCS 
family members to SOCS1 (and often methylated in many cancers as weil), lacked this 
abilîty in our study. This is a limited study however as SOCS2, and SOCS7 and CIS were 
unavailable and therefore not studied. However, it is worth nothing that not ail SOCS 
proteins are known to have negative effects on their targets. SOCS2 for example, though 
known to negatively regulate GH in low levels, can actually lead to increases in GH 
signaling when overexpressed [134]. It was also shown that SOCS2 (as weIl as SOCS6) 
can antagonize SOCS 1 signaling and lead to the degradation of SOCS l, so it would seem 
unlikely that SOCS2 overexpression would induce growth arrest [121]. The roles of 
SOCS7 and CIS in growth arrest are unknown and their interactions with other SOCS 
molecules less clear. It is known that SOCS7 can interact with ail SOCS molecules 
though it has yet to be shown that SOCS 7 negatively regulates SOCS 1. Why only SOCS 1 
is capable of inducing a permanent cell cycle arrest is unknoWn at this point. Although it 
shares a close similarity with SOCS3, there are still differences, among them a different 
sequence in the Cul box of SOCS 1 that allows it differential Cullin binding [89]. We 
have shown that mutating this sequence to resemble those of other SOCS molecules can 
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prevent SOCS 1 trom inducing growth arrest in U20S cells. Perhaps this unique Cul box 
sequence allows SOCS 1 to bind to other proteins involved in growth arrest pathways that 
other SOCS family proteins cannot, or perhaps the binding of Cul2 gives SOCSl a 
different group of substrate targets for degradation compared to other SOCS molecules 
which bind Cu15. It is also possible that other sequences in or near the SH2 domain of 
SOCSI allow it to target unique molecules. Or alternatively perhaps one or more of the 
specifie cytokines, JAKIStat pathways or other target proteins under control of SOCS 1 
happen to be the only ones under SOCS control that are involved in growth arrest 
pathways as weIl. 
Interestingly enough, sorne SOCS family members such as SOCS5 seern to 
actually promote cell growth. The mechanisms for this are unknown though it may be 
possible that SOCS5 acts as an oncogene. If SOCS5 targets proteins that inhibit growth, 
or shares a dual function as does SOCS2 with GH, it could be possible that SOCS5 
overexpression would promote growth, as we have demonstrated. Another explanation 
could lie in interactions between SOCS proteins. As rnentioned above SOCS family 
members have been previously shown to have overlapping functions which may interfere 
with one another [121J. SOCS2 expression in HEK293-T cells abolished SOCSl and 
SOCS3 inhibition of GH signalingpathway. SOCS2 mutants lacking a functional SOCS 
box failed to do so. The role and mechanisms by which SOCS molecules interact on one 
another is not c1ear, though the SOCS box and ability to fonn E3 Iigases seerns to be 
heavily involved. In low concentrations SOCS2 is able to reduce p-IFN Ievels in 
HEK293-T cells, a molecule typically inhibited by SOCS l, in higher concentrations 
SOCS2 leads to increases in p-IFN levels. This dual effect clouds the mechanisms of 
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SOCS2 interactions with SOCS1 and SOCS3. SOCS6 has been shown to directly lead to 
proteasomal degradation of SOCS 1, and its inhibition of SOCS 1 is interrupted by 
proteasomal inhibitors like cycloheximide. Furthermore it requires the recruitment of the 
Elongin BC complex to SOCS6. In this model SOCS family members are able to 
recognize the SOCS box domains of other SOCS molecules and regulate them via 
targeting them for proteasomal degradation. Degradation of SOCS 1 by other SOCS 
family members could erase the growth arrest pro gram initiated by SOCS 1. If the net 
effect of SOCS5 over expression favors SOCS 1 degradation or reduction of SOCS 
signaling, preventing the induction of growth arrest, than it may actually promote growth 
and proliferation, much in the same way SOCS2 overexpression does in the GH signaling 
pathway [121]. More study is required to determine if SOCS5 and SOCS 1 interact, and if 
SOCS5 negatively regulates the other SOCS molecules. As weIl further investigations 
into the roles of aIl SOCS molecules on growth arrest need to be explored further. At this 
time the exact outcome of interacting SOCS molecules and the effects on growth arrest 
are not weIl known, hence overexpression of one SOCS molecule at a time may not be 
the best way to elucidate their function. For this study we chose to focus solely on the 
involvement of SOCS 1 in growth arrest. 
We attempted to show dependency ofSOCS1 activity on the BC and Cul 
boxes, subdomains of the SOCS Box, since many functions ofSOCS1 require the SOCS 
box domain. There is currently much debate as to whether or not SOCS 1 binding to the 
Elongin BC complex actually leads to prote in stabilization or to proteasomal degradation 
of SOCS 1 [76, 77, 123, 124]. The results ofthis study offer no clear conclusion. When 
overexpressed the prote in levels of ~BC and ~Cul mutants are lower than wild-type 
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SOCS l though this is not seen with the ~Box mutants. Perhaps the formation of an 
in complete E3 ligase through binding to only the Elongin BC complex or the Cul/Rbx 
complex leads to degradation. The SOCS l ~Box mutant without any SOCS box perhaps 
has no recognition site for other SOCS molecules to bind and target it for proteasomal 
whereas epitopes may remain within the ~BC box and ~Cul box mutants to allow normal 
recognition and subsequent degradation. 
SOCS l has been shown to act as an adaptor protein linking the modules of an E3 
ligase together. This E3 ligase activity has been attributed to its negative regulation of the 
JAK/Stat signaling cascades. The results of this study show that SOCS l not only induces 
activity of the tumor suppressor p53 as weIl as its phosphorylation but also its 
downstream target p2I. Direct degradation of p5 3 would not lead to the growth arrest 
accompanied with over expression of SOCS l, so SOCS l must either target a negative 
regulator of p53 for degradation or act upon p53 in a way previously undescribed that 
leads to its activation. MDM2 levels remain unchanged in SOCS l transfected U20S 
cells, though it is possible SOCSI targets other E3 ligases regulating p53 such as COPI 
and Pirh2, this possibility needs to be explored before ruling out the obvious E3 ligase 
activity of SOCS 1 in leading to p53 activation. Cullin based E3 ligases are also capable 
ofmany other post transductional modifications such as neddylation and sumoylation 
[135-138]. Another Cullin based E3ligase, FBXOll, was recently shown to directly 
neddylate p53, leading to an increase in its transcriptional activity [139]. As weIl the role 
of SUMO upon p53 has begun to come under more intense study [140]. The possibility of 
SOCSI based E3 ligases regulating p53 through direct post transductional modification 
has not been explored in this study. Yet more and more ex amples ofneddylation and 
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sumoylation appearing to play important roles in regulating proteins, and important 
pathways, even the cell cycle, have begun to appear in recent literature [141, 142] . This 
dictates that the roles of these modifications and the enzymes that pro duce them require 
more study. 
While we were unable to directly demonstrate the dependency of the BC or Cul 
box domains for SOCS 1 induced growth arrest, we have identified a necessary residue 
within the Cul box domain of SOCS 1 for this activity. Kumara et al., originally 
identified a stretch of amino acids within the Cul box of SOCS 1 that differs from a 
conserved sequence found in aIl other SOCS family members [89]. Specifically deletion 
or mutation to the N198 residue aIt ers the IPLNP sequence in the Cul box of SOCS 1 to 
resemble the LPxP sequence found in aIl other SOCS family proteins. As weIl, both these 
modifications abolish the ability of SOCS 1 to induce growth arrest in the U20S ceIlline 
we studied. The Cul box of SOCS 1 resembles that of the VHL tumor suppressor, and 
both have been shown to bind to a Cul2/Rbxl complex. [74, 89]. Other SOCS members 
bind to Cul 51 Rbx 2 complex. VHL has also been shown to bind directly to p53 and 
stabilize p53 levels upon activation by both blocking MDM2 induced degradation and 
recruiting p53 modifying proteins [143]. Other students in our lab have demonstrated that 
SOCS 1 can form direct interactions with p53 (Calabresse et al. unpublished). AIso, VHL 
can induce growth arrest in different ceIllines [143]. Both SOCSI and VHL share a 
similar Cul box, unique from that of other SOCS 1 members, alteration of the Cul box of 
SOCS 1 to that of other SOCS proteins through mutations to N198 abolishes growth 
arrest. Hence, SOCS 1 can be acting in a manner very similar to VHL and can be acting as 
an adaptor prote in to recruit proteins to modify p53. This could explain the 
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phosphorylation of p53 at serine 15 seen in U20S cells overexpressing SOCS 1. The 
binding site for p53 is unknown but it could be likely that SOCS 1 can act as an adaptor 
protein for many complexes aside from an E3 ligase. 
1t is possible however that other proteins that protect p53 from ubiquitination or 
activate it through modifications bind to this region. In this model, the componehts of the 
E3 ligase could be in competition for binding sites within SOCS 1 with p53 and p53 
modifying proteins. However, the binding of p53 to SOCS 1 must be further explored. 
Another model would be SOCS 1 binding to Cul5IRbx2 allows it to degrade different 
targets than other SOCS molecules binding to Cul2/Rbx 1. This would give SOCS 1 a 
unique advantage and possibly allow it to degrade proteins which promote growth or 
proteins that act as a negative regulator of p53, inducing a growth arrest. Switching the 
Cul box sequence in theory would alter SOCS 1 so that it binds to Cul2/Rbx 1, not 
CuI5/Rbx2, preventing normal SOCS 1 function. We were unable to show Cul2 binding 
with SOCS 1 or the SOCS 1 mutants with the antibodies available to us, therefore we 
cannot assume that this is indeed the case with the SOCS 1 ôN198 or SOCS 1 N198P 
mutants. 
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Conclusion: 
We have shown that SOCSl appears to be the only member of the SOCS family 
of proteins capable of inducing a growth arrest phenotype. In primary cells, the growth 
arrest is manifested as premature senescence, this implicates SOCS 1 in a powerful anti-
tumor rriechanism, coinciding with its role as a tumor suppressor. Other members of the 
SOCS family do not share this ability and sorne appear to have roles as an oncogene. 
Furthermore, we have shown SOCS 1 can activate the p53 pathway. The exact 
mechanisms of this are not known and must be further explored. As weIl, we have shown 
a residue within SOCS 1 that is necessary for the growth arrest phenotype of SOCS 1. 
Since others in our lab have shown that SOCS 1 can bind p53 directly, we suggest that 
alternative binding to Cu15/Rbx2 or a differential binding domain within SOCS 1 allows 
SOCS 1 to bind to p53 and stabilize it directly. Possibly, p53 binds to SOCS 1 at one site 
and other proteins are recruited to SOCS] to modify and stabilize p53 through another 
site, which possibly contains the N198 residue. These results, although only preliminary, 
demonstrate the role of SOCS 1 in senescence as a possible role of SOCS] as a tumor 
suppressor which could act independent of its role in regulating JAK/Stat pathways. The 
activation ofp53 makes SOCS] an important protein ofinterest. Its widespread 
methylation in a variety of cancers further illustrates its importance. We suggest the full 
function of SOCSI remains a mystery and that it may have other roI es and functions 
independent of its E3 ligase activity. We conclude that further studies on the mechanisms 
of p53 activation by SOCS l, and on the role played by the Cul box and the Nl98 residue 
on growth arrest, are required. 
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